The effect of APOE genotype on Alzheimer’s disease risk is influenced by sex and DHA status

Pontifex, Matthew, Vauzour, David ORCID: and Minihane, Anne-Marie ORCID: (2018) The effect of APOE genotype on Alzheimer’s disease risk is influenced by sex and DHA status. Neurobiology of Aging, 69. pp. 209-220. ISSN 0197-4580

[thumbnail of Accepted manuscript] PDF (Accepted manuscript) - Accepted Version
Restricted to Repository staff only until 31 December 2099.

Request a copy
[thumbnail of Accepted manuscript]
PDF (Accepted manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (613kB) | Preview


An APOE- ε4 genotype is the strongest common genetic determinant of Alzheimer’s disease (AD). The pleiotropic nature of apolipoprotein E, has made elucidation of the aetiological basis difficult to establish which is further complicated by the fact that the penetrance of the APOE- ε4 allele is modulated by sex, age, and nutrition. A greater metabolic consequence of the APOE- ε4 allele is likely to contribute to the fact that two thirds of AD patients are female. A higher tissue status of the marine n-3 fatty acid docosahexaenoic acid (DHA), is associated with a lower AD risk. However, APOE- ε4 carriers appear less sensitive to the neurocognitive benefits, which may be due to defective blood brain barrier transport of DHA exacerbated by ageing and possibly sex. This suggests higher DHA requirements in this large population subgroup. This narrative review will consider the influence of sex and DHA in modulating APOE- ε4 mediated AD risk.

Item Type: Article
Uncontrolled Keywords: apolipoprotein e,blood brain barrier,docosahexaenoic acid,lipid metabolism,lipid transport,poly-unsaturated fatty acids,sdg 14 - life below water ,/dk/atira/pure/sustainabledevelopmentgoals/life_below_water
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 16 May 2018 13:31
Last Modified: 22 Oct 2022 03:47
DOI: 10.1016/j.neurobiolaging.2018.05.017

Actions (login required)

View Item View Item